Purchase this article with an account.
Yinan Han, Jiang Qian, Yifei Yuan, Yingwen Bi, Yiqun Yao, Kang Xue, Chenghua Wei, Jie Guo, ; Management of Malignant Eyelid Tumors by Primary Reconstruction: Evaluation of Long-term Outcomes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6371.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study long-term outcomes of primary reconstruction in surgical excision of malignant tumors.
We analyzed the data of 46 eyes with eyelid malignant tumors undertaken surgical excision during 2005 to 2008 in Shanghai Eye and ENT Hospital. The cancer type, location, type of the procedure, local recurrence, lymph node enlargement and survival rate were evaluated.
Among 46 cases, basal cell carcinoma (21 cases), sebaceous gland carcinoma (19 cases), squamous cell carcinoma(4 cases), lymphoma(1 cases) and Merkel cell carcinoma(1 case) were included. Various techniques were used, such as Hughes procedure, Cutler-Beard procedure, myocutaneous advancement flap, semicircular rotational flap, lateral cantholysis, periosteal strip, free autogenous tarsal graft, full-thickness skin graft and glabella flap, et al. Median follow-up was 59.7±12.9 months (minimum/maximum 15 to 84). According to the Kaplan-Meier survival estimate, the overall 5 year, 7 year survival rate was 93.5%, 91.3% respectively. 5 year tumor- free survival rate was 91.1%. During follow-up period, local recurrence occurred in two cases who refused further treatment and still alive by last follow-up. Cervical lymph node enlargement was detected in two cases, followed by lymph node debridement. Both of them were in good condition till now. Four patients died, two of metastasis, one of old age, and one of primary esophageal carcinoma. Mild entropion and extropion were occurred in two cases. One had trichiasis. Others acquired normal eyelid position. Satisfaction in comfort and appearance was achieved in 87% cases.
Eyelid reconstruction techniques could effectively repair the defects after resection of eyelid malignant tumors and lead to satisfactory clinical results. Active surveillance is still mandatory.
This PDF is available to Subscribers Only